Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants.

By K. Posner, M. Oquendo, Madelyn S. Gould, B. Stanley, M. Davies. American Journal of Psychiatry, 2007

966 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Evidence-based guidelines for treating bipolar disorder: revised third edition Recommendations from the British Association for Psychopharmacology (2009, neutral): “The controversy arising from how self-harm or suicidality should be identified as an adverse reaction has been particularly problematic (Gibbons et al., 2015; Posner et al., 2007).”
Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. (2007, methodology): “The FDA, in collaboration with Columbia University, evaluated the effects on suicidality of nine antidepressants used in 24 acute RCTs (16 MDD, 4 OCD, 2 generalized anxiety disorder, 1 SAD, and 1 ADHD; Hammad et al., 2006; Posner et al., 2007).”
Suicide and Suicidal Behavior (2008, methodology): “We use the terminology for and definitions of suicidal behavior outlined in recent consensus papers on this topic (29–32).”
The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults (2011, background): “Food and Drug Administration to classify retrospective reports of potentially suicidal adverse events and to provide interpretable data to inform pivotal drug safety questions (29).”